Publicacións en colaboración con investigadores/as de Complejo Hospitalario de Toledo (27)

2024

  1. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

2023

  1. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2022

  1. SEOM-GEICO clinical guidelines on endometrial cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 625-634

  2. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  2. Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

    JOURNAL OF DRUG ASSESSMENT, Vol. 8, Núm. 1, pp. 62-69

  3. Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "sEXSAT-Q"

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1

  4. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  5. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

    Scientific Reports, Vol. 9, Núm. 1

  6. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

    Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125

  7. SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 31-45

2018

  1. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

    JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308

  2. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

  3. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

  2. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

  3. Neoadjuvant therapy with weekly nanoparticle albumin-bound paclitaxel for luminal early breast cancer patients: Results from the nabrax study (GEICAM/2011-02), a multicenter, non-randomized, phase ii trial, with a companion biomarker analysis

    Oncologist, Vol. 22, Núm. 11, pp. 1301-1308

2016

  1. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer

    Oncologist, Vol. 21, Núm. 2, pp. 150-155